drugset / Trial / NCT02779114
RETRO (REduction of Therapy in RA Patients in Ongoing Remission)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 3, multicenter, randomized, open, prospective, controlled, parallel-group intervention study in 318 patients with Rheumatoid Arthritis. The study is composed of 3 phases: a pre-randomization phase for up to 10 days followed by a 1-year randomized, open three arm treatment phase for each patient, followed by a 5-year observational phase for all patients still in remission.
Timeline
- Start
- 2009-01
- Primary completion
- 2017-12
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abatacept | Other / unclassified | — | — |
| Subject | Adalimumab | Monoclonal antibody | — | — |
| Subject | Azathioprine | Small molecule | — | — |
| Subject | Certolizumab | Protein / enzyme biologic | — | — |
| Subject | Cyclosporine | Peptide | — | — |
| Subject | Etanercept | Protein / enzyme biologic | — | — |
| Subject | Golimumab | Monoclonal antibody | — | — |
| Subject | Hydroxychloroquine | Small molecule | — | — |
| Subject | Infliximab | Monoclonal antibody | — | — |
| Subject | Leflunomide | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | — |
| Subject | Mycophenolate Mofetil | Small molecule | — | — |
| Subject | Sulfasalazine | Small molecule | — | — |
| Subject | Tocilizumab | Monoclonal antibody | — | — |